Company
Otsuka
Otsuka has 41 drugs tracked on RxWires: 4 post-market, 2 approved, 15 in Phase 3, 10 in Phase 2, 1 in Phase 1/2, 8 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Aripiprazole | Post-Market | Irritability Associated With Autistic Disorder |
| ABILIFY MYCITE | Post-Market | Schizophrenia |
| abilify maintena | Post-Market | Schizophrenia |
| aspirin | Post-Market | Noncardioembolic Cerebral Infarction |
| DEXTROSE | Approved | |
| VOYXACT | Approved | |
| Brexpiprazole (OPC-34712) | Phase 3 | Schizophrenia |
| OPC-34712FUM/ Brexpiprazole fumarate | Phase 3 | Schizophrenia |
| Antidepressant + Aripiprazole | Phase 3 | Major Depressive Disorder |
| 180mg of ETC-1002(bempedoic acid) | Phase 3 | Hyper-low-density Lipoprotein (LDL) Cholesterolemia |
| Tolvaptan Suspension | Phase 3 | Autosomal Recessive Polycystic Kidney (ARPKD) |
| EB-1020 (Centanafadine) 164.4 mg | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) |
| Quabodepistat | Phase 3 | Rifampicin-Resistant Pulmonary Tuberculosis |
| Centanafadine XR | Phase 3 | Attention-deficit/Hyperactivity Disorder |
| SEP-363856 | Phase 3 | Generalized Anxiety Disorder |
| OPA-15406 | Phase 3 | Atopic Dermatitis (AD) |
| JNT-517 | Phase 3 | Phenylketonuria |
| Antidepressant + Placebo | Phase 3 | Major Depressive Disorder |
| OPC-1085EL | Phase 3 | Open Angle Glaucoma or Ocular Hypertension |
| Delamanid + OBR | Phase 3 | Multidrug-resistant Tuberculosis |
| Aripiprazole (Abilify®) IM Depot Injection | Phase 3 | Schizophrenia |
| Fludarabine/Busulfan x 4 days | Phase 2 | Multiple Myeloma |
| dasatinib | Phase 2 | Pancreatic Cancer |
| Sibeprenlimab | Phase 2 | IgA Nephropathy |
| AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination) | Phase 2 | Depressive Disorder, Treatment-Resistant |
| Ponatinib 30mg OD | Phase 2 | Chronic Myeloid Leukemia |
| Calcium (13C)Carbonate | Phase 2 | Gastroesophageal Reflux Disease |
| Busulfan | Phase 2 | MDS |
| OPS-2071 | Phase 2 | Crohn's Disease |
| OPC-64005 | Phase 2 | Adult Attention Deficit Hyperactivity Disorder |
| VIS954 | Phase 2 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis |
| 10 mg OPC-167832 | Phase 1/2 | Pulmonary TB |
| STAT Inhibitor OPB-111077 | Phase 1 | Acute Myeloid Leukemia |
| OCV-501 | Phase 1 | Acute Myeloid Leukemia |
| SEP363856 | Phase 1 | Narcolepsy |
| NDI-5001 | Phase 1 | Diabetes Insipidus |
| OPF-110 | Phase 1 | |
| HBM7020 | Phase 1 | Rheumatoid Arthritis |
| 14C-SEP-380135 | Phase 1 | Schizophrenia |
| OPC-34712 | Phase 1 | Schizophrenia |
| Procaterol | Not Applicable | Cough |
Latest
Follow Otsuka on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.